Global Cancer Biomarkers Market

Global Cancer Biomarkers Market Size, Share, Growth Analysis, By Profiling Technology(Omic Technologies, Imaging Technologies), By Biomolecules(Genetic Biomarkers, Protein Biomarkers), By Cancer(Breast Cancer, Lung Cancer), By Application(Diagnostics, Drug Discovery and Development) - Industry Forecast 2023-2030


Report ID: SQMIG35A2775 | Region: Global | Published Date: February, 2024 | Pages: 157 | Tables: 124 | Figures: 72

Global Cancer Biomarkers Market Insights

Global Cancer Biomarkers Market size was valued at USD 13.24 Billion in 2022 and is poised to grow from USD 14.83 Billion in 2023 to USD 29.49 Billion by 2031, growing at a CAGR of 13.6% in the forecast period (2024-2031).

The projected growth of the global cancer biomarkers market reflects a notable surge in prevalence across diverse cancer types such as breast, prostate, and lung cancer. This uptick in cancer incidence serves as a driving force propelling market expansion during the forecast period.

Additionally, the rising significance of biological and targeted drug therapies in cancer treatment fuels the demand for effective biomarkers. Technological advancements further bolster this growth trajectory, enhancing the accuracy and reliability of cancer biomarkers, thereby improving diagnostic capabilities and treatment monitoring.

Market snapshot - 2024-2031

Global Market Size

USD 13.24 Billion

Largest Segment

Lung Cancer

Growth Rate

13.6% CAGR

Global Cancer Biomarkers Market ($ Bn)
Country Share for North America Region (%)
Global Cancer Biomarkers Market By Type (%)

To get more reports on the above market click here to Buy The Report

Global Cancer Biomarkers Market Segmental Analysis

The global cancer biomarkers market is segmented into five segments i.e. by profiling technology, cancer type, biomolecule, application and region. Based on Profiling Technology the market is segmented as, Omic Technologies, Imaging Technologies, Immunoassays, Cytogenetics-based Tests. Based on Biomolecules the market is segmented as, Genetic Biomarkers, Protein Biomarkers, Epigenetics, Glyco-biomarkers. Based on Cancer Type the market is segmented as, Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Others. Based on Application the market is segmented as, Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, Others. Based on Region the market is segmented as, North America, U.S., Canada, Mexico, Europe, Germany, UK, Italy, France, Spain, Rest of Europe, Asia-Pacific, Japan, China, India, South Korea, Australia, Rest of Asia-Pacific, LAMEA, Brazil, Saudi Arabia, Rest of LAMEA.

Analysis by Biomolecule

Genetic biomarkers have emerged as a dominant force within the market, commanding a significant share owing to their widespread utilization, remarkable reliability, and streamlined analysis protocols. Their prevalence stems from their capacity to facilitate highly accurate and dependable detection methods. In fact, genetic and proteomic biomarkers collectively contribute to the detection of over 85% of malignancies reported globally.

Epigenetics has garnered widespread acceptance and significance within the realm of cancer diagnostics, heralding a new era in understanding the intricate mechanisms underlying the disease. A considerable volume of research efforts is underway among various stakeholders, aiming to comprehensively analyze key epigenetic modifications closely associated with cancer.

Analysis by Type

Breast cancer stood out as the largest segment within the market landscape, wielding considerable influence by itself. Cumulatively, breast, lung, and prostate cancer collectively commanded a substantial revenue share, surpassing the 40% mark. This dominance was fueled by pivotal factors, notably the increasing awareness campaigns advocating for early testing and detection, a critical catalyst in steering the market's trajectory.

The forecast period anticipates significant acceleration in the growth of lung cancer within the market landscape. This surge is primarily propelled by a burgeoning array of diagnostic tests enhancing in on EGFR and BRAF mutations, serving as pivotal biomarkers crucial for diagnosing non-small cell lung cancer. The escalating emphasis on specific mutations via diagnostic testing signifies a pivotal evolution in precision medicine, heralding a paradigm shift towards more precise and targeted diagnoses. This focused approach allows for a deeper understanding of genetic variations and alterations, enabling healthcare practitioners to pinpoint and identify specific mutations associated with various diseases.

Global Cancer Biomarkers Market By Type , 2022 (%)

To get detailed analysis on other segments, Request For Sample Report

Global Cancer Biomarkers Market Regional Insights

In 2022, North America asserted its dominance as the frontrunner in the global industry, commanding a substantial revenue share of over 44.00%. This leadership position owes its strength to several pivotal factors, including the region's high disease burden, heightened consumer awareness regarding the crucial role of biomarkers in healthcare, and proactive government initiatives supporting advancements in this specialized field.

Meanwhile, the Asia Pacific region is poised to witness a promising CAGR throughout the forecast period, buoyed by multiple influential factors. Primarily, the escalating prevalence of cancer within this region significantly contributes to the anticipated robust growth trajectory. Furthermore, the Asia Pacific area presents an ideal environment for conducting clinical trials, fostering a conducive atmosphere for research and development endeavors in the realm of biomarkers.

Global Cancer Biomarkers Market By Region, 2024-2031
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Global Cancer Biomarkers Market Dynamics

Drivers

Presence of Potential Pipeline Candidates to Boost the Market

  • Numerous pharmaceutical entities are vigorously channeling investments into pioneering research and development endeavors focused on novel biomarkers tailored for cancer diagnosis and treatment. Several promising candidates are nearing the culmination of their development phases, poised to make significant strides upon their launch. These prospective biomarkers hold immense potential to revolutionize the landscape of cancer care, offering heightened accuracy and efficacy in diagnosis and treatment.

Restraints

Lack of Reimbursement Policies for Biomarker Testing

  • The growing incidence of cancer worldwide and the rising necessity for diagnostic tests stand in contrast to a significant limitation in the cancer biomarker market. the absence of comprehensive reimbursement policies for biomarker tests across both emerging and developed nations. This shortfall inhibits the widespread adoption of these crucial diagnostic tools, constraining the demand for biomarkers globally. Additionally, the high cost associated with cancer diagnosis and treatment, especially prevalent in emerging economies, presents a formidable barrier.

Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report

Global Cancer Biomarkers Market Competitive Landscape

The competitive environment of the global Cancer Biomarkers Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry.

Top Player’s Company Profiles

  • F. Hoffmann-LA Roche Ltd.
  • Siemens AG
  • Thermo Fisher Scientific, Inc.
  • Merck & Co, Inc.
  • Agilent Technologies Inc.
  • Bristol-Myers Squibb Company
  • Qiagen N.V.
  • Exact Sciences Corporation
  • Novartis AG
  • Bio-Rad Laboratories
  • Hologic, Inc.
  • bioMérieux SA
  • Abbott Laboratories
  • PerkinElmer, Inc.
  • Illumina

Recent Developments

  • In March 2023, Servier made waves by partnering with QIAGEN to pioneer the development of a groundbreaking mIDH1 companion diagnostic test. This test is poised to bolster Servier's Hemato-Oncology Portfolio, specifically aiding in the identification of patients grappling with acute myeloid leukemia (AML). This strategic collaboration signifies a substantial leap forward in enhancing diagnostic capabilities within AML treatment.
  • February 2023 marked a pivotal moment as Roche expanded its collaboration with Janssen, signaling a concerted effort to advance personalized healthcare solutions by integrating companion diagnostics. This extended partnership significantly broadens the spectrum of activities, now encompassing a diverse array of companion diagnostics within their portfolio. This comprehensive collection encompasses tissue and blood-based biomarkers, digital pathology, and cutting-edge sequencing technologies, reinforcing their commitment to pushing the boundaries of personalized healthcare solutions.

Global Cancer Biomarkers Key Market Trends

  • The cancer biomarkers market is positioned for significant expansion in the forthcoming decade, propelled by a confluence of pivotal factors. Central to this growth is the rising awareness among patients and healthcare practitioners concerning the critical role of early detection in addressing malignancies. This heightened awareness fosters a proactive stance toward early diagnosis, encouraging timely interventions that bear the potential for more effective treatment outcomes.

Global Cancer Biomarkers Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.

The global cancer biomarkers market analysis reveals a dynamic marketplace with a number of standout trends and difficulties. The anticipated growth in the industry stems from several key drivers, notably the growing importance of companion diagnostics alongside the escalating prevalence of cancer. This trajectory is further propelled by substantial investments in biomarker research, fostering significant innovations derived from ongoing scientific exploration. An illustrative instance is the October 2022 allocation of USD 4.6 million in funding from the National Institutes of Health to researchers at Boston University, specifically aimed at pioneering advancements in lung cancer biomarkers. Moreover, the landscape benefits from continual technological advancements that drive the development of biomarker-based diagnostics, enhancing their precision and efficacy.

Report Metric Details
Market size value in 2022 USD 13.24 Billion
Market size value in 2031 USD 29.49 Billion
Growth Rate 13.6%
Base year 2022
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Profiling Technology
    • Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics-based Tests
  • Biomolecules
    • Genetic Biomarkers, Protein Biomarkers, Epigenetics, and Glyco-biomarkers
  • Cancer
    • Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, and Others
  • Application
    • Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, and Others
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • F. Hoffmann-LA Roche Ltd.
  • Siemens AG
  • Thermo Fisher Scientific, Inc.
  • Merck & Co, Inc.
  • Agilent Technologies Inc.
  • Bristol-Myers Squibb Company
  • Qiagen N.V.
  • Exact Sciences Corporation
  • Novartis AG
  • Bio-Rad Laboratories
  • Hologic, Inc.
  • bioMérieux SA
  • Abbott Laboratories
  • PerkinElmer, Inc.
  • Illumina
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Global Cancer Biomarkers Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Global Cancer Biomarkers Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Global Cancer Biomarkers Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Cancer Biomarkers Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Cancer Biomarkers Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Global Cancer Biomarkers Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

SPEAK TO AN ANALYST

FAQ's

Global Cancer Biomarkers Market size was valued at USD 13.24 Billion in 2022 and is poised to grow from USD 14.83 Billion in 2023 to USD 29.49 Billion by 2031, growing at a CAGR of 13.6% in the forecast period (2024-2031).

The competitive environment of the global Cancer Biomarkers Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. Leading brands invest in research and development to introduce new flavors, packaging formats, and health-focused variations to cater to changing consumer preferences. They often set the trends in the industry. 'F. Hoffmann-LA Roche Ltd.', 'Siemens AG', 'Thermo Fisher Scientific, Inc.', 'Merck & Co, Inc.', 'Agilent Technologies Inc.', 'Bristol-Myers Squibb Company', 'Qiagen N.V.', 'Exact Sciences Corporation', 'Novartis AG', 'Bio-Rad Laboratories', 'Hologic, Inc.', 'bioMérieux SA', 'Abbott Laboratories', 'PerkinElmer, Inc.', 'Illumina'

Numerous pharmaceutical entities are vigorously channeling investments into pioneering research and development endeavors focused on novel biomarkers tailored for cancer diagnosis and treatment. Several promising candidates are nearing the culmination of their development phases, poised to make significant strides upon their launch. These prospective biomarkers hold immense potential to revolutionize the landscape of cancer care, offering heightened accuracy and efficacy in diagnosis and treatment.

The cancer biomarkers market is positioned for significant expansion in the forthcoming decade, propelled by a confluence of pivotal factors. Central to this growth is the rising awareness among patients and healthcare practitioners concerning the critical role of early detection in addressing malignancies. This heightened awareness fosters a proactive stance toward early diagnosis, encouraging timely interventions that bear the potential for more effective treatment outcomes.

In 2022, North America asserted its dominance as the frontrunner in the global industry, commanding a substantial revenue share of over 44.00%. This leadership position owes its strength to several pivotal factors, including the region's high disease burden, heightened consumer awareness regarding the crucial role of biomarkers in healthcare, and proactive government initiatives supporting advancements in this specialized field.

Speak With Our Analyst

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Cancer Biomarkers Market

Product ID: SQMIG35A2775

$5,300
BUY NOW GET SAMPLE